/TDOC
TDOC Stock - Teladoc Health, Inc.
Healthcare|Medical - Healthcare Information ServicesNYSE
$7.23+1.26%
+$0.09 (+1.26%) • Dec 19
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.29
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).78
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.38
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+14.1%upside
Target: $8.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TDOC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.16 – $7.30
TARGET (TP)$8.25
STOP LOSS$6.65
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.04
52W High$15.21
52W Low$6.35
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.57B | $2.60B | $2.41B | $2.03B | $1.09B |
| Gross Profit | $1.82B | $1.84B | $1.66B | $1.38B | $703.13M |
| Gross Margin | 70.8% | 70.8% | 69.1% | 68.0% | 64.3% |
| Operating Income | $-1,020,886,000 | $-248,553,000 | $-13,653,214,000 | $-265,630,999 | $-506,421,000 |
| Net Income | $-1,001,245,000 | $-220,368,000 | $-13,659,531,000 | $-428,793,000 | $-485,136,000 |
| Net Margin | -39.0% | -8.5% | -567.5% | -21.1% | -44.3% |
| EPS | $-5.87 | $-1.36 | $-84.60 | $-2.73 | $-5.36 |
Company Overview
Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
18%
Hold / Neutral
17
77%
Sell / Underperform
1
5%
Analyst Consensus🔴 Bearish
4 Bullish18 Neutral/Bearish
Price Targets
$30
Average Target
↑ 316.5% Upside
Now
$8
Low
$30
Average
$96
High
Based on 22 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Equal Weight | $8.5 |
| November 13th 2025 | BMO Capital Markets | Initiation | Market Perform | $8 |
| July 25th 2025 | Mizuho | Initiation | Neutral | $10 |
| November 15th 2024 | Goldman | Initiation | Buy | $14 |
| September 17th 2024 | Jefferies | Reiterated | Hold | $10← $8 |
| February 29th 2024 | Cantor Fitzgerald | Initiation | Overweight | $22 |
| February 26th 2024 | Leerink Partners | Initiation | Market Perform | $17 |
| January 17th 2024 | DA Davidson | Downgrade | Neutral | $22← $33 |
| January 3rd 2024 | Barclays | Initiation | Overweight | $26 |
| April 12th 2023 | Stephens | Initiation | Equal Weight | $25 |
| February 23rd 2023 | SVB Securities | Upgrade | Outperform | $34 |
| October 24th 2022 | Guggenheim | Upgrade | Neutral | - |
| September 16th 2022 | KeyBanc Capital Markets | Initiation | Sector Weight | - |
| September 7th 2022 | Truist | Initiation | Hold | $35 |
| August 17th 2022 | Guggenheim | Downgrade | Sell | $25 |
Earnings History & Surprises
TDOCBeat Rate
83%
Last 18 quarters
Avg Surprise
+18.5%
EPS vs Estimate
Beats / Misses
15/3
Last 12 quarters
Latest EPS
$-0.21
Q4 2025
EPS Surprise History
Q1 24
+22.7%
$-0.17vs$-0.22
Q2 24
-4.3%
$-0.49vs$-0.47
Q3 24
+22.2%
$-0.28vs$-0.36
Q4 24
+34.5%
$-0.19vs$-0.29
Q1 25
-33.3%
$-0.28vs$-0.21
Q2 25
+42.4%
$-0.19vs$-0.33
Q3 25
+29.6%
$-0.19vs$-0.27
Q4 25
+19.2%
$-0.21vs$-0.26
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.19 | — | — | — |
Q4 2025 | Oct 29, 2025 | $-0.26 | $-0.21 | +19.2% | ✓ BEAT |
Q3 2025 | Jul 29, 2025 | $-0.27 | $-0.19 | +29.6% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $-0.33 | $-0.19 | +42.4% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-0.21 | $-0.28 | -33.3% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $-0.29 | $-0.19 | +34.5% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $-0.36 | $-0.28 | +22.2% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $-0.47 | $-0.49 | -4.3% | ✗ MISS |
Q1 2024 | Feb 20, 2024 | $-0.22 | $-0.17 | +22.7% | ✓ BEAT |
Q4 2023 | Oct 24, 2023 | $-0.37 | $-0.35 | +5.4% | ✓ BEAT |
Q3 2023 | Jul 25, 2023 | $-0.44 | $-0.40 | +9.1% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $-0.51 | $-0.37 | +27.5% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $-0.27 | $-0.23 | +14.8% | ✓ BEAT |
Q4 2022 | Oct 26, 2022 | $-0.59 | $-0.45 | +23.7% | ✓ BEAT |
Q3 2022 | Jul 27, 2022 | $-0.71 | $-0.44 | +38.0% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $-0.55 | $-0.47 | +14.5% | ✓ BEAT |
Q1 2022 | Feb 22, 2022 | $-0.59 | $-0.07 | +88.1% | ✓ BEAT |
Q4 2021 | Oct 27, 2021 | $-0.70 | $-0.53 | +24.3% | ✓ BEAT |
Q3 2021 | Jul 27, 2021 | $-0.59 | $-0.86 | -45.8% | ✗ MISS |
Latest News
Barclays Initiates Coverage On Teladoc Health with Equal-Weight Rating, Announces Price Target of $8.5
➖ NeutralBenzinga•Dec 9, 2025, 04:22 PM•Also:
B of A Securities Maintains Neutral on Teladoc Health, Lowers Price Target to $8
📉 NegativeBenzinga•Nov 25, 2025, 12:19 PM
BMO Capital Initiates Coverage On Teladoc Health with Market Perform Rating, Announces Price Target of $8
➖ NeutralBenzinga•Nov 13, 2025, 11:10 AM
Evercore ISI Group Maintains In-Line on Teladoc Health, Lowers Price Target to $8
➖ NeutralBenzinga•Oct 30, 2025, 05:04 PM
Update: Teladoc Health Q3 Adj. EPS $(0.20) Beats $(0.27) Estimate, Sales $626.439M Beat $625.913M Estimate
📈 PositiveBenzinga•Oct 29, 2025, 08:57 PM
Teladoc Health Sees Q4 GAAP EPS $(0.25)-$(0.10) vs $(0.17) Est; Sees Sales $622.000M-$652.000M vs $634.855M Est
➖ NeutralBenzinga•Oct 29, 2025, 08:10 PM
Teladoc Health Narrows FY2025 GAAP EPS Guidance from $(1.35)-$(1.00) to $(1.25)-$(1.10) vs $(1.12) Est; Narrows FY2025 Sales Guidance from $2.501B-$2.548B to $2.510B-$2.539B vs $2.522B Est
➖ NeutralBenzinga•Oct 29, 2025, 08:09 PM
Teladoc Health Q3 EPS $(0.28) Misses $(0.26) Estimate, Sales $626.439M Beat $625.913M Estimate
➖ NeutralBenzinga•Oct 29, 2025, 08:08 PM
TriNet Appoints Former Teladoc CFO Mala Murthy As New Finance Chief, Kelly Tuminelli Transitions To Special Advisor Role
📈 PositiveBenzinga•Oct 29, 2025, 11:08 AM•Also:
Teladoc Health Reaffirms Its 2025 FY Consolidated Revenue Of $2.501B-$2.548B And Adjusted EBITA Outlook Issued On July 29, 2025
📈 PositiveBenzinga•Oct 23, 2025, 08:45 PM
Teladoc Health Announces CFO Mala Murthy Will Step Down On November 21, 2025 And Search Has Begun For Her Successor
📉 NegativeBenzinga•Oct 23, 2025, 08:13 PM
Citigroup Maintains Neutral on Teladoc Health, Raises Price Target to $10.5
➖ NeutralBenzinga•Oct 21, 2025, 04:01 PM•Also:
Teladoc Health Announced The Launch Of A New Offering To Help Hospitals And Health Systems Address Workplace Violence
📈 PositiveBenzinga•Oct 14, 2025, 10:07 AM
Evercore ISI Group Maintains In-Line on Teladoc Health, Raises Price Target to $9
📈 PositiveBenzinga•Oct 8, 2025, 01:24 PM
Teladoc shares are trading higher following bullish comments from Citron Research.
📈 PositiveBenzinga•Oct 3, 2025, 03:19 PM
Key deals this week: Gildan Activewear, Western Union, Sapiens, Perplexity, Teladoc Health and more
➖ NeutralSeeking Alpha•Aug 16, 2025, 07:15 PM•Also: ,
Teladoc Health acquires UpLift, expanding access to mental health care services
📈 PositiveSeeking Alpha•Apr 30, 2025, 08:23 PM
Frequently Asked Questions about TDOC
What is TDOC's current stock price?
Teladoc Health, Inc. (TDOC) is currently trading at $7.23 per share. The stock has moved +1.26% today.
What is the analyst price target for TDOC?
The average analyst price target for TDOC is $8.25, based on 1 analyst.
What sector is Teladoc Health, Inc. in?
Teladoc Health, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NYSE exchange.
What is TDOC's market cap?
Teladoc Health, Inc. has a market capitalization of $1.28 billion, making it a small-cap company.
Does TDOC pay dividends?
No, Teladoc Health, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAZTA
Azenta, Inc.
$34.43
Mkt Cap: $1.6B
EVO
Evotec SE
$2.95
Mkt Cap: $1.0B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
NVCR
NovoCure Limited
$12.84
Mkt Cap: $1.4B
OMCL
Omnicell, Inc.
$46.84
Mkt Cap: $2.2B
OMDA
Omada Health
$14.50
Mkt Cap: $0.8B
PGNY
Progyny, Inc.
$26.63
Mkt Cap: $2.3B
PHR
Phreesia, Inc.
$16.55
Mkt Cap: $1.0B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
SDGR
Schrödinger, Inc.
$17.66
Mkt Cap: $1.3B
Explore stocks similar to TDOC for comparison